Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Paratek Pharmaceuticals
Pharma
Paratek buys Optinose, rhinosinusitis spray Xhance for up to $330M
In a move to expand its portfolio beyond antibiotics, Paratek has bought out Optinose and its chronic rhinosinusitis nasal spray Xhance for $330M.
Kevin Dunleavy
Mar 20, 2025 11:23am
Paratek's pneumonia antibiotic Nuzyra clinches trial win
Jul 19, 2024 8:28am
Paratek's $462M sale under threat from investor NexPoint
Jun 28, 2023 2:03pm
Paratek bought by Novo Holdings, Gurnet Point for $462M
Jun 6, 2023 4:21pm
What will become of Trump's 'onshore' drug production effort?
Dec 22, 2020 3:00am
Michigan CDMO builds new plant to meet U.S.-made drug demand
Jun 30, 2020 9:00am
